Atossa Genetics raises funds for MACST breast cancer system
Jun 28, 2011
The Mammary Aspirate Specimen Cytology Test System is being dubbed a "pap test for breast cancer," where samples come from the nipple aspirate fluid. The new system may be instrumental in diagnosing breast cancer.
Atossa Genetics is the company behind the MACST System and the group has recently raised $6.6 million, more than its intended target of $6 million.
"We are excited to have achieved this critical funding milestone, which will allow us to make our patented, FDA-cleared MASCT system available to physicians and patients beginning in the Northwestern United States this year," said Steven C. Quay, the President and CEO of Atossa Genetics.
Breast cancer affects one out of every eight women in the U.S. and more than 200,000 new female patients each year, according to the American Cancer Society.